Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is produced ...

AstraZeneca is making another go at developing a medicine like Ozempic. The U.K. pharma giant purchased licensing rights to a candidate in early-stage clinical trials. But that drug will need ...

AstraZeneca PLC (LSE:AZN) had a mixed day of news, with the bright spots of a foray into anti-obesity drugs and an upgrade to its full-year outlook somewhat clouded by news about potential lawsuits ...

Nov 14 (Reuters) - Drugmaker AstraZeneca (AZN.L) said on Tuesday its cancer drug Imfinzi given along with chemoradiotherapy (CRT) failed to meet its main goal in a late-stage trial to treat ...

AstraZeneca CEO Pascal Soriot discusses Q3 earnings, oncology revenue, gene therapy treatments, what's to come for the company and the U.S. supply chain. Donald Trump Being Kicked off 2024 Ballot ...

Shares of AstraZeneca rose as much as 4.2% in early trade after the company raised its full-year guidance for core earnings per share and total revenue excluding Covid-19 medicines after beating ...

Proactive Investors - Barclays (LON:BARC) Capital has issued an optimistic assessment of AstraZeneca PLC (LON:AZN)'s shares, recommending an 'overweight' position with a target price of £135, a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

AstraZeneca is scheduled to report results for the third quarter of the year on Thursday. Here is what you need to know: SALES: The Anglo-Swedish pharmaceutical giant is expected to report revenue ...

Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is ...